 Ranibizumab
"Ranibizumab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A recombinant humanized monoclonal antibody fragment that binds VEGF-A to prevent its binding to VEGFR-1 and VEGFR-2 receptors. This activity reduces vessel permeability and angiogenesis in the treatment of neovascular age-related MACULAR DEGENERATION.
| Descriptor ID |
D000069579
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.060.868 D12.776.124.790.651.114.224.060.868 D12.776.377.715.548.114.224.200.868
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Ranibizumab".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
- Ranibizumab [D12.776.124.486.485.114.224.060.868]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
- Ranibizumab [D12.776.124.790.651.114.224.060.868]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
- Ranibizumab [D12.776.377.715.548.114.224.200.868]
Below are MeSH descriptors whose meaning is more specific than "Ranibizumab".
This graph shows the total number of publications written about "Ranibizumab" by people in this website by year, and whether "Ranibizumab" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 0 | 2 | 2 | | 2010 | 0 | 5 | 5 | | 2011 | 0 | 1 | 1 | | 2013 | 0 | 1 | 1 | | 2014 | 0 | 1 | 1 | | 2021 | 0 | 1 | 1 | | 2023 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Ranibizumab" by people in Profiles.
-
Choi W, Nensel AK, Droho S, Fattah MA, Mokashi-Punekar S, Swygart DI, Burton ST, Schwartz GW, Lavine JA, Gianneschi NC. Thrombospondin-1 proteomimetic polymers exhibit anti-angiogenic activity in a neovascular age-related macular degeneration mouse model. Sci Adv. 2023 10 13; 9(41):eadi8534.
-
Eilts SK, Pfeil JM, Poschkamp B, Krohne TU, Eter N, Barth T, Guthoff R, Lagr?ze W, Grundel M, Br?nder MC, Busch M, Kalpathy-Cramer J, Chiang MF, Chan RVP, Coyner AS, Ostmo S, Campbell JP, Stahl A. Assessment of Retinopathy of Prematurity Regression and Reactivation Using an Artificial Intelligence-Based Vascular Severity Score. JAMA Netw Open. 2023 01 03; 6(1):e2251512.
-
Levin AM, Chaya CJ, Kahook MY, Wirostko BM. Intraocular Pressure Elevation Following Intravitreal Anti-VEGF Injections: Short- and Long-term Considerations. J Glaucoma. 2021 12 01; 30(12):1019-1026.
-
Bravo-Filho V, Logan P, Zoroquiain P, Aldrees S, Vil? N, Oweida A, Belfort Neto R, Burnier MN. Effects of ranibizumab and amfenac on the functional abilities and radiosensitivity of uveal melanoma cells. Arq Bras Oftalmol. 2019 Jan-Feb; 82(1):38-44.
-
Desapriya E, Khoshpouri P, Al-Isa A. Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Patient-Centered Outcomes From a Randomized Clinical Trial. Am J Ophthalmol. 2017 05; 177:232-233.
-
Maguire MG, Martin DF, Ying GS, Jaffe GJ, Daniel E, Grunwald JE, Toth CA, Ferris FL, Fine SL. Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology. 2016 08; 123(8):1751-1761.
-
Altaweel MM, Daniel E, Martin DF, Mittra RA, Grunwald JE, Lai MM, Melamud A, Morse LS, Huang J, Ferris FL, Fine SL, Maguire MG. Outcomes of eyes with lesions composed of >50% blood in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT). Ophthalmology. 2015 Feb; 122(2):391-398.e5.
-
Formoso G, Marata AM, Magrini N, Bero L. A clearer view of evidence in treating macular degeneration: off-label policies and independent research. Cochrane Database Syst Rev. 2014 Sep 15; (9):ED000090.
-
Gewaily DY, Grunwald JE, Pistilli M, Ying GS, Maguire MG, Daniel E, Ostroff CP, Fine SL. Delayed patchy choroidal filling in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Am J Ophthalmol. 2014 Sep; 158(3):525-31.e2.
-
Daniel E, Toth CA, Grunwald JE, Jaffe GJ, Martin DF, Fine SL, Huang J, Ying GS, Hagstrom SA, Winter K, Maguire MG. Risk of scar in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014 Mar; 121(3):656-66.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|